Lidocaine transdermal patch - EpiCept

Drug Profile

Lidocaine transdermal patch - EpiCept

Alternative Names: ADL 87223; LidoPAIN BP; LidoPAIN HM; LidoPAIN SP; LidoPAIN TV

Latest Information Update: 20 Jul 2015

Price : $50

At a glance

  • Originator EpiCept Corporation
  • Developer EpiCept Corporation; Immune Pharmaceuticals Inc
  • Class Acetanilides; Class Ib antiarrhythmics; Local anaesthetics; Small molecules
  • Mechanism of Action Sodium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Back pain
  • Discontinued Headache; Postoperative pain; Tinnitus

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 08 Jul 2015 Immune Pharmaceuticals regains exclusive rights to develop, commercialise and license LidoPAIN® BP
  • 08 Jul 2015 Phase-II clinical trials in Back pain in USA (Transdermal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top